Novo Nordisk’s Oral GLP-1 Launch Beats Forecasts, Yet India Price War and Market Caution Check Enthusiasm

Novo Nordisk's oral Wegovy crushes Q1 forecasts with $2.26B revenue, yet a fast-maturing India generics threat and CagriSema pipeline doubt keep shares below peak.

Novo Nordisk has delivered its strongest operational surprise in months with the oral Wegovy tablet, but the stock remains mired well below its peak as a fast-maturing generics threat in India and lingering pipeline uncertainty temper the optimism. The contrast between a red-hot product rollout and a lukewarm reception on the trading floor sums up the delicate balancing act facing the Danish drugmaker.

Wegovy tablet crushes consensus

The oral version of Wegovy generated 2.26 billion Danish kroner in first-quarter revenue, nearly double the Jefferies consensus forecast of 1.16 billion. Prescriptions topped 1.3 million during the period and have exceeded 2 million since the launch. In the week leading to 17 April, weekly prescriptions surpassed 200,000, making Novo Nordisk claim the strongest GLP-1 volume debut in US history.

The momentum is building quickly. In its first full week on the market, the oral product generated over 18,000 prescriptions. Wegovy now accounts for 65% of all new oral GLP-1 prescriptions in the United States. The company plans to bring the tablet outside the US in the second half of 2026, pending regulatory approvals.

Amazon opens a new distribution channel

Just as the oral Wegovy gathers speed, Amazon Pharmacy has begun offering the oral version of Ozempic for adults with type 2 diabetes. The tablet comes in three dosages and can be ordered with a prescription for same-day delivery. Amazon is rolling out the service across roughly 3,000 cities initially and aims to reach 4,500 by the end of 2026.

The logistics push broadens Novo Nordisk’s digital reach and reduces dependence on traditional pharmacy channels. The company already runs access programmes with Weight Watchers and GoodRx. For investors, the question is whether faster distribution can offset the pricing pressure building elsewhere.

India delivers a preview of the post-patent world

India has become an early test case for Novo Nordisk’s pricing strategy after the US patent on semaglutide expired in March 2026. More than a dozen local manufacturers have launched copycat products, including Sun Pharma, Dr. Reddy’s, Cipla and Zydus Lifesciences. Novo Nordisk responded by cutting prices for Ozempic by 38% and Wegovy by 48%. Despite the reductions, sales of its diabetes and obesity drugs rose 40% in April.

The dynamic illustrates the strategic tension ahead. Lower prices support volumes and market share but squeeze margins. India offers a glimpse of what other emerging markets may face as exclusivity windows close.

CagriSema pipeline edges closer

Alongside the access and generics story, the next major catalyst sits in the pipeline. Novo Nordisk has submitted a filing to the US Food and Drug Administration for CagriSema, a combination of cagrilintide and semaglutide for weight management. The agency is expected to rule by the end of 2026.

Clinical data provide the firepower. In the REDEFINE 1 study, patients taking CagriSema lost an average of 22.7% of their body weight after 68 weeks, compared with 2.3% on placebo; 91.9% achieved at least a 5% reduction. Separately, cagrilintide as a monoproduct delivered an 11.8% weight loss over the same period, and Novo Nordisk plans to launch a phase 3 programme called RENEW for that candidate.

Financials and stock remain under pressure

The company has modestly improved its outlook for 2026, now expecting a constant currency decline in revenue and operating profit of 4% to 12%, versus the previous forecast of a 5% to 13% drop. Reported sales jumped 32% on a currency-adjusted basis, but that included a special benefit from a 340B programme adjustment; stripping that out, revenues fell 4%. Among the established products, injectable Wegovy rose 12% to 18.2 billion kroner, slightly below expectations, while Ozempic fell 8% but beat consensus.

The shares closed on Friday at €38.56, giving a year-to-date loss of 13.70% and a 12-month slide of 34.93%. The stock remains about 45% below its all-time high. Although the price has recovered some ground above its 50-day moving average, it still trades below the 200-day line.

Analysts stay on the sidelines

Wall Street remains cautious. Citi lifted its price target to 290 Danish kroner from 275 but kept a neutral rating. BMO Capital, Barclays, Morgan Stanley, Deutsche Bank and Kepler Capital have all maintained hold recommendations. The market is waiting for clearer signals on the pipeline and the competitive dynamics.

Novo Nordisk is also investing in artificial intelligence. In April 2026 it struck a strategic partnership with OpenAI, with pilot projects under way in research, manufacturing and commercial operations. Full integration is targeted by the end of the year.

What to watch next

The next major inflection point comes on 5 August, when Novo Nordisk reports half-year results. Until then, the market will focus on three variables: the weekly prescription trajectory of the oral Wegovy, the expansion of Amazon delivery, and any regulatory updates on CagriSema. With the launch beating expectations and the generics threat still localised for now, the pieces for a turnaround are in place — but confidence on the Street will take more than one quarter to rebuild.